Interpreting Emerging Data in Relapsed and Refractory Multiple Myeloma

In this segment, Dr. Ajay Nooka invites Dr. Surbhi Sidana to discuss how recent data presented at major scientific meetings, including ASH 2025, are shaping the management of relapsed and refractory multiple myeloma. Dr. Sidana highlights how newer therapeutic approaches are demonstrating promising outcomes in earlier lines of relapse, prompting clinicians to reconsider traditional treatment sequencing. The discussion focuses on how these data are interpreted within the context of existing standards of care, emphasizing the importance of patient selection, prior treatment exposure, and clinical trial eligibility when applying findings to real-world practice. Dr. Sidana also underscores the need to balance efficacy with practical considerations such as toxicity, access, and feasibility in different care settings. This segment provides insight into how evolving evidence is being thoughtfully integrated into clinical decision-making in multiple myeloma.